World's First Recombinant Botulinum Toxin Type A New Drug Received Marketing Approval in China: a Technological Revolution pioneered by Claruvis Pharmaceutical
CHONGQING, China, April 28, 2026 /PRNewswire/ — Chongqing Claruvis Pharmaceutical Co., Ltd. recently announced that the China’s National Medical Products Administration (NMPA) has approved its Retoxin® (recombinant botulinum toxin type A, project code YY001) for the temporary improvement of moderate-to-severe glabellar lines in adult patients. Retoxin® is the world’s first approved recombinant botulinum toxin type […]





